Early results of stereotactic body radiation therapy for the treatment of residual hepatocellular carcinoma after chemoembolization

  • Đồng Đức Hoàng Đại học Y Dược Thái Nguyên
  • Mai Hồng Bàng Bệnh viện Trung ương Quân đội 108
  • Thái Doãn Kỳ Bệnh viện Trung ương Quân đội 108
  • Nguyễn Tiến Thịnh Bệnh viện Trung ương Quân đội 108
  • Bùi Quang Biểu Bệnh viện Trung ương Quân đội 108
  • Nguyễn Đình Châu Bệnh viện Trung ương Quân đội 108

Main Article Content

Keywords

Hepatocellular carcinoma, stereotactic body radiation therapy, transarterial chemoembolization, tumor response

Abstract

Objective: To evaluate early results of stereotactic body radiation therapy (SBRT) compared with repeated transarterial chemoembolization (TACE) in the treatment of residual hepatocellular carcinoma after chemoembolization. Subject and method: A prospective, controlled intervention study on 42 patients with hepatocellular carcinoma (HCC) treated with SBRT and 38 patients treated with TACE using DC Beads. Assessing clinical, laboratory, AFP, tumor response (according to mRECIST) at 3, 6 months after treatment. Result: The clinical response in group I (61.9%) was different from that in group II (23.7%), p<0.05. AFP response in group I (56.5%) tended to be higher than in group II (42.9%), p>0.05. Tumor response at 6 months in group I (complete response 51.4%, partial response 8.1%) was different from that in group II (21.9% and 3.1%), p<0.05. Conclusion: SBRT for clinical response and tumor response rates was different compared with repeat TACE for residual HCC patients after TACE.

Article Details

References

1. Yao E, Chen J, Zhao X et al (2018) Efficacy of stereotactic body radiotherapy for recurrent or residual hepatocellular carcinoma after transcatheter arterial chemoembolization. Biomed Res Int 2018: 5481909.
2. Schaub SK, Hartvigson PE, Lock MI et al (2018) Stereotactic body radiation therapy for hepatocellular carcinoma: Current trends and controversies. Technol Cancer Res Treat 17: 1533033818790217.
3. Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68(2): 723-750.
4. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1): 52-60.
5. Muscari F, Maulat C (2020) Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): Is this 50-year biomarker still up-to-date? Transl Gastroenterol Hepatol 5: 46.
6. Toro A, Ardiri A, Mannino M et al (2014) Effect of pre- and post-treatment alpha-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: A retrospective study. BMC Surg 14: 40.
7. Zhu AX, Finn RS, Kang YK et al (2021) Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer 124(8): 1388-1397.
8. Yu JI, Yoo GS, Cho S et al (2018) Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. Radiat Oncol J 36(1): 25-34.

Article Sidebar

PDF (Tiếng Việt)
Published
May 5, 2022
DOI: https://doi.org/10.52389/ydls.v17i3.1177
Issue
Volume 17 - No 3/2022
Section
Articles
How to Cite
Đức Hoàng Đồng, Hồng BàngM., Doãn KỳT., Tiến ThịnhN., Quang BiểuB., & Đình ChâuN. (2022). Early results of stereotactic body radiation therapy for the treatment of residual hepatocellular carcinoma after chemoembolization. Tạp Chí Y Dược lâm sàng 108, 17(3). https://doi.org/10.52389/ydls.v17i3.1177